Atopic
8
2
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Dietary Intervention on Atopy
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Tacrolimus Versus Hydrocortisone in Atopic Dermatitis
Normal Blood, Bone Marrow and Buccal Mucosa Protocol
Pediatric ACEs Screening and Resiliency Study